Companies / ATH

ALTERITY THERAPEUTICS LIMITED

ASX:ATHPharmaceuticals, Biotechnology & Life Sciences
229.2M shares on issueASX (delayed) · snapshot 28 Oct 2026277.9M fully diluted+21.3% if every option and right converts$0.24price · delayed$55.0MMarket capAt the previous close. On a day the price moves, shares × today’s price will differ. Prices delayed.

Today’s holders own 82.4% of what they think they own, once every option and right converts.

High
Dilution risk

Share count grew 115% in 24 months; 4 cash raises in 24 months; runway 4–8 quarters

MinimalVery high
Absolute levels — not a ranking against other companies.
Cash runway4.4 quarters of funding
Share-count growth (24m)115.4%
Raise cadence (24m)4 cash raises
Options & rights overhang21.3% of shares
In-the-money supply1.0% of shares
Pending proposed issuesopen proposed issue (Appendix 3B)

ALTERITY THERAPEUTICS LIMITED's ordinary share count, adjusted for a 1-for-50 share consolidation in June 2026, grew 115.4% between July 2024 and September 2026, its latest share-count filing, to 229M shares. The company completed 4 capital raises in the past 24 months for total proceeds of A$102.1M, most recently a A$20.0M placement in September 2025. Options and rights on issue could convert into 49M new shares, representing 21.3% of current shares, with 1% in the money; the nearest expiry is November 2026. The company has more than 4 quarters of funding at the recent spend rate. One proposed securities issue (Appendix 3B) is pending, with an expected issue date in November 2026.

AI-generated summary of this page's cited filings · updated 23 Oct 2026
Quick answers · 3

Is ATH raising capital?

Alterity Therapeutics has 1 proposed issue of securities pending under Appendix 3B as at 28 Oct 2026; the most recent raise announced is Placement of $20.0M on 8 Sept 2025.

How much cash does ATH have?

In its quarterly cash report for the quarter ended 30 June 2026, Alterity Therapeutics reported $37.3M of cash and estimated 5.2 quarters of funding available at its current rate of spending. That is the company's own estimate.

When do ATH's options expire?

Unexercised options and rights equal 21.3% of Alterity Therapeutics's shares on issue; the nearest expiry is Nov 2026.

Get told when this changes
Get ATH alerts
Free for up to 2 companies. A daily email when ATH raises money, files a new share issue, drops below 2 quarters of cash or moves risk level.
21.3%
Options & rights overhang
1.0%
In the moneyAn option whose exercise price is below the last closing share price, so converting it pays. These are the options most likely to become new shares soon. supply · most strikes not on record
0
Raises · last 12 months
4.4 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Adjusted for the 1-for-50 consolidation (1 June 2026). Latest count 229.2M per ASX (delayed) (snapshot 28 Oct 2026).
100M150M200MDec 24Nov 25Oct 261-for-50 consolidationCash raise · 8 Sept 2025Cash raise · 10 Feb 2025Cash raise · 7 Apr 2025Cash raise · 3 Feb 2025229.2M

Cash runway

4.4 qtrs OURS
More than four quarters of funding at the recent spend rate.
Funds operations to about Nov 2027 at the reported spend rate.
$31.7M cash after burn.
FILED 5.2 qtrs · $37.3M cash · quarter ended 30 June 2026
OURS our estimate, carried to todayOURSOur estimate for today. We take the cash in the company’s latest cash report, deduct spending since at its reported rate, and, for quarterly filers, add raises announced after it. It moves daily; announced money may not all be received yet.FILED as the company reportedFILEDAs the company stated it in its latest cash report. Dated to the end of that period, it does not change until the next report.
Free account
14 cash reports on record — Cash runway history
Cash, net spend and cover trend from every Appendix 4C/5B and 4D/4E on record up to 30 June 2026.
Free account: 2 full company unlocks every month, no card.
Unlock ATH freeSee plans

Issuance timeline

Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityOn issue, per this filingSource
23 Oct 20263G · unquotedATH : ORDINARY FULLY PAID229.2MAppendix 3G
23 Oct 20263G · unquotedATH : ORDINARY FULLY PAID229.2MAppendix 3G
16 Sept 20262A · quoted issueATH : ORDINARY FULLY PAID229.2MAppendix 2A
8 Sept 20262A · quoted issueATH : ORDINARY FULLY PAID229.1MAppendix 2A
1 Sept 20262A · quoted issueATH : ORDINARY FULLY PAID220.7MAppendix 2A
Free account
52 filings on record — Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Free account: 2 full company unlocks every month, no card.
Unlock ATH freeSee plans

Securities on issue over time

Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.

Free account
Securities on issue, by class
How the share count and each option and rights class moved, month by month, with every number in a table.
Free account: 2 full company unlocks every month, no card.
Unlock ATH freeSee plans

Capital raises

4 cash raises in the last 24 months · 0 in the last 12 months

every 2.4 monthsaverage gap between raises
13.6 monthssince the most recent
3 Feb 2025 – 8 Sept 2025first to most recent in this window
$20.0M
Placement
At 1.2c, 7.7% below the last close
8 Sept 2025 COMPLETE
Free account
13 issues (incl. 8 exercises or conversions) on record — Full raise history
Issue price, shares issued, brokers and stated purpose for every raise on record.
Free account: 2 full company unlocks every month, no card.
Unlock ATH freeSee plans

Forward supply

Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.

Free account
18 dated events on record — Forward supply calendar
Option expiries and proposed issues on one forward timeline, with the securities each could add.
Free account: 2 full company unlocks every month, no card.
Unlock ATH freeSee plans

Placement capacity

How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.

No estimate — a share consolidation inside the last 12 months puts the filings and the share count in different units.
Free account
Placement capacity — LR 7.1 / 7.1A
The filings behind the figure: every Appendix 3B in the window with what it says was issued under 7.1 and 7.1A, each row linked to its filing, and how many shares are left.
Free account: 2 full company unlocks every month, no card.
Unlock ATH freeSee plans

Pending proposed issues

1 proposed issue pending — Appendix 3B lodged, securities not yet issued. New shares from these issues are not in the counts above until quoted.
Paid plan
1 pending issue on record — Pending issue detail
Size, price, fees, broker and placement-capacity usage for each pending issue.
Unlocks on a paid plan
See plans

Options & convertible securities

21.3%
Options & rights overhang · of current shares
1.0%
In-the-money supply · most strikes not on record
48.8M
Potential new shares
Nov 2026
Nearest expiry
What a price move would switch on
24.4M48.8M$0.24 now0.25× today ($0.06) — 0 of the priced supply in the money, 0.0% of shares on issue0.5× today ($0.12) — 0 of the priced supply in the money, 0.0% of shares on issue0.75× today ($0.18) — 2.1M of the priced supply in the money, 0.9% of shares on issue1× today ($0.24) — 2.4M of the priced supply in the money, 1.0% of shares on issue1.25× today ($0.30) — 5.8M of the priced supply in the money, 2.5% of shares on issue1.5× today ($0.36) — 10.0M of the priced supply in the money, 4.4% of shares on issue2× today ($0.48) — 16.8M of the priced supply in the money, 7.3% of shares on issue3× today ($0.72) — 20.9M of the priced supply in the money, 9.1% of shares on issue5× today ($1.20) — 24.1M of the priced supply in the money, 10.5% of shares on issue10× today ($2.40) — 24.3M of the priced supply in the money, 10.6% of shares on issue0.25×0.5×0.75×now1.25×1.5×2×3×5×10×

At $0.24 today, 2.4M securities are in the money (1.0% of shares on issue) — a floor, because an exercise price is on record for only 49.9% of this supply. No more priced supply until 1.25× today’s price, which takes it to 5.8M (2.5% of shares).

  • Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
  • 24.4M (50.1% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
CodeSecurityTypeExercise priceExpiryOn issueSource
ATHAAGOptionsPrice-triggered$1.1929 Nov 2026230kFiling
ATHAAEOptionsPrice-triggered$1.8829 Nov 2026200kFiling
ATHAAHOptionsPrice-triggered$0.5319 Dec 2026160kFiling
ATHOAOptionsPrice-triggered, no exercise price stated—26 Feb 202724.4MFiling
ATHAAKOptionsPrice-triggered$0.5030 Dec 20273.4MFiling
ATHABOptionsPrice-triggered$0.1513 Mar 20291.3MFiling
ATHAAOptionsPrice-triggered$0.2013 Mar 2029353kFiling
ATHACOptionsPrice-triggered$0.1521 Mar 2029800kFiling
ATHADOptionsPrice-triggered$0.501 July 2030300kFiling
ATHAFOptionsPrice-triggered$0.438 Aug 20306.2MFiling
ATHAEOptionsPrice-triggered$0.658 Aug 2030230kFiling
ATHAAMOptionsPrice-triggered$0.2813 Jan 2031870kFiling
ATHAGOptionsPrice-triggered$0.2826 Mar 20311.2MFiling
ATHAJOptionsPrice-triggered$0.3015 Apr 20314.2MFiling
ATHAKOptionsPrice-triggered$0.4515 Apr 2031540kFiling
ATHALOptionsPrice-triggered$1.0015 June 20313.0MFiling
—OptionsPrice-triggered$0.288 Oct 20311.3MFiling

“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.

Free account
17 option lines on record — In-the-money value & price ladder
What each line is worth in the money today, the price ladder to the next tranche that converts, and the filing description behind every code.
Free account: 2 full company unlocks every month, no card.
Unlock ATH freeSee plans

Director dealings

DateDirectorTypeSharesOptionsOtherValueSource
31 Aug 2026David StamlerSell234k48k——3Y notice
31 Aug 2026Peter MarksOther191k600k—$24k3Y notice
15 June 2026Julian BarbaczyOther incentive—2.0M——3Y notice
15 June 2026Lawrence GozlanOther incentive121k1.0M——3Y notice
Free account
19 notices on record — Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Free account: 2 full company unlocks every month, no card.
Unlock ATH freeSee plans

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Free account: 2 full company unlocks every month, no card.
Create free account

Latest announcements

23 Oct 2026Proposed issue of securities - ATH
23 Oct 2026Notification regarding unquoted securities - ATH
23 Oct 2026Notification regarding unquoted securities - ATH
21 Oct 2026Notice of Annual General Meeting/Proxy Form
21 Oct 2026Changes to Managing Director Terms of Employment
19 Oct 2026Alterity to Present at the Craig-Hallum Biotech Conference
9 Oct 2026Alterity to Present at Canaccord Drug and Device Conference
5 Oct 2026Alterity Presents New Analyses of ATH434 Phase 2 Data in MSA
25 Sept 2026Date of AGM and Closing Date for Director Nominations
23 Sept 2026Corporate Presentation September 2026
18 Sept 2026Alterity Therapeutics to Present at ASX SMIDcaps Conference
16 Sept 2026Application for quotation of securities - ATH
8 Sept 2026Cleansing Notice Under Section 708A
8 Sept 2026Application for quotation of securities - ATH
3 Sept 2026Alterity to Present at Cantor Global Healthcare Conference
2 Sept 2026Change of Director's Interest Notice - Stamler
2 Sept 2026Change of Director's Interest Notice - Marks
1 Sept 2026Application for quotation of securities - ATH
31 Aug 2026Alterity Therapeutics Filed Form 20-F and XBRL Data with SEC
31 Aug 2026$P$4.2M Options Underwriting Agreement Executed

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.